Compositions and methods for treating and preventing heart tissue degeneration and uses thereof
View Patent ↗The present invention provides compositions useful for cardiac therapy comprising a cyclin-associated agent. The present invention also provides kits for use in delivering a cyclin-associated agent to cardiac cells in a subject, comprising the composition of the present invention and a catheter. The present invention additionally provides a methods for enhancing cardiac function; promoting regeneration of cardiac tissue; inducing endogenous myocardial regeneration; and preventing or treating heart failure in a subject in need thereof by augmenting cyclin in cells.
1. A method of treating a subject, the method comprising administering a composition comprising a cyclin A2 protein to the subject, wherein the cyclin A2 protein has an amino acid sequence having greater than about 85% homology to SEQ ID NO: 1 and promotes both G1/S and G2/M transitions, and wherein the subject has heart failure or heart tissue damage or degeneration.
2. The method of claim 1 wherein the cyclin A2 protein has an amino acid sequence having greater than about 90% homology to SEQ ID NO: 1.
3. The method of claim 1 , wherein the cyclin A2 protein is naturally occurring.
4. The method of claim 3 , wherein the cyclin A2 protein is a human protein.
5. The method of claim 1 , wherein the subject is a human.
6. The method of claim 1 , wherein the subject experiences cardiomyocyte hyperplasia, improved cardiac ejection fraction, and/or increased cardiac output after administration of the composition.
7. The method of claim 1 , wherein the composition is administered to the subject parenterally.
8. The method of claim 1 , wherein the composition is administered to the subject by a catheter inserted into the subject's heart tissue.
9. The method of claim 1 , wherein the composition is administered to the subject by contacting the composition with heart tissue cells or side-population progenitor cells of the subject in vivo.
10. The method of claim 1 , wherein the composition is administered to the subject by contacting the composition with cells in vitro then introducing the cells into the subject.
11. The method of claim 10 , wherein the cells are introduced into the subject through a catheter inserted into the subject's heart tissue.
12. The method of claim 10 , wherein the cells are heart tissue cells.
13. The method of claim 10 , wherein the cells are side-population progenitor cells.
14. The method of claim 10 , wherein contacting is accomplished by delivering a viral vector capable of producing said composition.
15. A method of treating a subject, the method comprising administering a composition comprising a cyclin A2 protein to the subject, wherein the cyclin A2 protein has an amino acid sequence having greater than about 85% homology to SEQ ID NO:1 and promotes both G1/S and G2/M transitions, and wherein the subject has a family history of heart failure or heart tissue damage or degeneration.
16. The method of claim 15 , wherein the cyclin A2 protein is naturally occurring.
17. The method of claim 15 , wherein the cyclin A2 protein is a human protein.
18. The method of claim 15 , wherein the subject is a human.
19. The method of claim 15 , wherein the subject experiences cardiomyocyte hyperplasia, improved cardiac ejection fraction, and/or increased cardiac output after administration of the composition.
20. The method of claim 15 , wherein the composition is administered to the subject parenterally.
21. The method of claim 15 , wherein the composition is administered to the subject by a catheter inserted into the subject's heart tissue.
22. The method of claim 15 , wherein the composition is administered to the subject by contacting the composition with heart tissue cells or side-population progenitor cells of the subject in vivo.
23. The method of claim 15 , wherein the composition is administered to the subject by contacting the composition with cells in vitro then introducing the cells into the subject.
24. The method of claim 15 , wherein the cells are introduced into the subject through a catheter inserted into the subject's heart tissue.
25. The method of claim 23 , wherein the cells are heart tissue cells.
26. The method of claim 23 , wherein the cells are side-population progenitor cells.
27. The method of claim 23 , wherein contacting is accomplished by delivering a viral vector capable of producing said composition.
28. The method of claim 15 wherein the cyclin A2 protein has an amino acid sequence having greater than about 90% homology to SEQ ID NO: 1.